The shares of COVID-19 vaccine developer Moderna Inc. show best dynamics among S&P 500 index fund securities.

The cost of shares of Moderna, co-founded by Noubar Afeyan, who is also the chairman of its Board of Directors, has grown by 267% from early 2021.

In the first quarter of the year Moderna gained $5,9 billion revenue and signed contracts on delivery of vaccines for 2012 worth $12 billion.

As of August 23, Moderna’s capitalization surpasses $166 billion.